A Phase Ib Open-Label, Multi-Center, Dose Escalation Trial of BI 764532 Given as Monotherapy Administered by Repeated Intravenous Infusions in Patients with Glioma Expressing DLL3
Details
A Phase Ib open-label, multi-center, dose escalation trial of
BI 764532 given as monotherapy administered by repeated
intravenous infusions in patients with glioma expressing DLL3
Eligibility
You can join if...
Eligibility Criteria
-Signed and dated written informed consent form (ICF1 and ICF2) in accordance with ICH-GCP and local legislation prior to admission to the trial
Tumours must be positive for DLL3 expression (defined as staining in >50% of tumour cells) by IHC on archived tumour tissue according to central pathology review
Adequate liver, bone marrow, and renal function
Exclusion Criteria
-Presence of extracranial metastatic or leptomeningeal disease
Previous treatment with therapies targeting DLL3
-Prior treatment with bevacizumab or other anti-VEGF or
anti-angiogenic treatment within 6 months prior to first
administration of BI 764532